Edit Symbol List
Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages.
Don't know the stock symbol? Use the
Symbol Lookup tool.
Alphabetize the sort order of my symbols
Investing just got easier…
Sign up now to become a NASDAQ.com member and begin receiving instant notifications when key events occur that affect the stocks you follow.Access Now
ETFs with CELG as a Top 10 Holding*
|Weighting||ETF Name (Symbol)||100-Day Price Change (%)|
|10.09%||VanEck Vectors Biotech ETF (BBH)||+1.25 (1.22%)|
|8.86%||iShares Nasdaq Biotechnology Index Fund (IBB)||-6.43 (-2.39%)|
|4.07%||PowerShares Dynamic Pharmaceuticals (PJP)||+1.97 (3.21%)|
|3.55%||Columbia Select Large Cap Growth ETF (RWG)||-10.12 (-20.65%)|
|2.89%||PowerShares DWA Healthcare Momentum Portfolio (PTH)||+0.97 (2.22%)|
Company Description (as filed with the SEC)
Celgene Corporation, together with its subsidiaries (collectively "we," "our," "us," "Celgene" or the "Company"), is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through next-generation solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. Celgene Corporation was incorporated in the State of Delaware in 1986. Our primary commercial stage products include REVLIMID®, POMALYST®/IMNOVID®, ABRAXANE®, OTEZLA®, VIDAZA®, azacitidine for injection (generic version of VIDAZA®), THALOMID® (sold as THALOMID® or Thalidomide CelgeneTM outside of the United States), and ISTODAX®. In addition, we earn revenue through licensing arrangements. ... More ...
Where does CELG fit in the risk graph?
|Annual EPS Est:||$4.08|
|Quarterly EPS Est:||1.24|